Evidence map›Paper›PMID 37373187›Full record

ReviewInternational journal of molecular sciences2023

Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options.

Maria Manou, Dimitrios S Kanakoglou, Theodoros Loupis, Dimitrios M Vrachnos, Stamatios Theocharis, Athanasios G Papavassiliou, Christina Piperi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Maria ManouDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Dimitrios S KanakoglouDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-7735-2029
Theodoros LoupisHaematology Research Laboratory, Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece.
Dimitrios M VrachnosHaematology Research Laboratory, Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece.
Stamatios TheocharisFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Athanasios G PapavassiliouDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-5803-4527
Christina PiperiDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-2701-0618
National and Kapodistrian University of Athens · GRAcademy of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salivary gland tumors (SGTs) comprise a rare and heterogenous category of benign/malignant neoplasms with progressively increasing knowledge of the molecular mechanisms underpinning their pathogenesis, poor prognosis, and therapeutic treatment efficacy. Emerging data are pointing toward an interplay of genetic and epigenetic factors contributing to their heterogeneity and diverse clinical phenotypes. Post-translational histone modifications such as histone acetylation/deacetylation have been shown to actively participate in the pathobiology of SGTs, further suggesting that histone deacetylating factors (HDACs), selective or pan-HDAC inhibitors (HDACis), might present effective treatment options for these neoplasms. Herein, we describe the molecular and epigenetic mechanisms underlying the pathology of the different types of SGTs, focusing on histone acetylation/deacetylation effects on gene expression as well as the progress of HDACis in SGT therapy and the current status of relevant clinical trials.

Indexed as

Brain NeoplasmsSalivary Gland NeoplasmsAcetylationHistone Deacetylase InhibitorsHistone DeacetylasesHistonesHumansHistone Deacetylase InhibitorsHistone DeacetylasesHistonesadenoid cystic carcinomaepigenetic modificationsHDACHDAC inhibitorshistone acetylationhistone deacetylationmucoepidermoid carcinomasalivary gland tumors

Identifiers

PMID37373187
PMCPMC10298439
OpenAlexW4380631494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.